Glycoprotein 130 (gp130) is a key transmembrane protein required by IL‐6 receptor family members to engage in trans‐signaling, which triggers a pro‐inflammatory response.[33] Studies have indicated that sgp130Fc, which selectively binds to the IL‐6/sIL‐6R complex, significantly lowers IL‐6 levels in treated animals compared to placebo.[41] In our studies, we find that sgp130Fc treatment in hippocampus effectively alleviates the depression and anxiety behaviors induced by CSDS, and also alleviates atrocytes atrophy. Here, IL6 is linked to depressive symptom measurement.